These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29622797)

  • 21. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
    Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC
    Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-Humanized Mouse Model to Study Bone Morphogenetic Protein (BMP) Signaling in Tumor Xenografts.
    Newman J; NeMoyer R; Zloza A; Langenfeld J
    Methods Mol Biol; 2019; 1891():257-262. PubMed ID: 30414139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of an ALK2-biased BMP type I receptor kinase inhibitor.
    Mohedas AH; Xing X; Armstrong KA; Bullock AN; Cuny GD; Yu PB
    ACS Chem Biol; 2013; 8(6):1291-302. PubMed ID: 23547776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
    Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
    Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
    Wang J; Wang HY; Shen Y; Liang D; Wang HY; Zhang SQ; Cao YX; Cao L
    Anticancer Drugs; 2019 Oct; 30(9):900-908. PubMed ID: 30913062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor effects of a novel chromosome region maintenance 1 (CRM1) inhibitor on non-small cell lung cancer cells in vitro and in mouse tumor xenografts.
    Wang S; Han X; Wang J; Yao J; Shi Y
    PLoS One; 2014; 9(3):e89848. PubMed ID: 24595136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q; Dong H; Mo J; Zhang Y; Huang J; Ouyang S; Shi S; Zhu K; Qu X; Hu W; Liu P; Wang Y; Zhang X
    Theranostics; 2021; 11(2):824-840. PubMed ID: 33391507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective CDK7 inhibition with BS-181 suppresses cell proliferation and induces cell cycle arrest and apoptosis in gastric cancer.
    Wang BY; Liu QY; Cao J; Chen JW; Liu ZS
    Drug Des Devel Ther; 2016; 10():1181-9. PubMed ID: 27042010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
    Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
    Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
    Ponader S; Chen SS; Buggy JJ; Balakrishnan K; Gandhi V; Wierda WG; Keating MJ; O'Brien S; Chiorazzi N; Burger JA
    Blood; 2012 Feb; 119(5):1182-9. PubMed ID: 22180443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts.
    Tang N; Zhang Q; Fang S; Han X; Wang Z
    Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling.
    Garulli C; Kalogris C; Pietrella L; Bartolacci C; Andreani C; Falconi M; Marchini C; Amici A
    Cell Signal; 2014 Feb; 26(2):352-62. PubMed ID: 24280125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
    Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
    Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
    Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
    Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity.
    Liu Z; Han C; Dong C; Shen A; Hsu E; Ren Z; Lu C; Liu L; Zhang A; Timmerman C; Pu Y; Wang Y; Chen M; Qiao J; Fu YX
    Sci Immunol; 2019 Aug; 4(38):. PubMed ID: 31399492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.